ClinicalTrials.Veeva

Menu
R

RFSA Dermatology | Castle Hills

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Remibrutinib
Dupilumab
LOU064

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 4 total trials

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

The purpose of this trial is:1. to assess the efficacy, pharmacokinetics, and safety of remibrutinib vs. placebo in adolescents from 12 to \< 18 year...

Enrolling
Chronic Spontaneous Urticaria
Drug: placebo
Drug: LOU064 (blinded)
Locations recently updated

This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension...

Enrolling
Chronic Inducible Urticaria
Drug: Remibrutinib
Other: Placebo
Recently updated

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participant...

Active, not recruiting
Chronic Spontaneous Urticaria
Drug: LOU064 (blinded)
Drug: Placebo

The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a...

Active, not recruiting
Moderate-to-Severe Atopic Dermatitis
Atopic Eczema
Other: Topical emollient (moisturizer)
Drug: dupilumab

Trial sponsors

Novartis logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems